Compassionate Use of Vidutolimod

NCT06063746•Regeneron Pharmaceuticals

View on ClinicalTrials.gov

Summary

Provide Compassionate Use of Vidutolimob

Detailed Description

Compassionate use is only available to patients who transitioned from a previous vidutolimod (CMP-001) study.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•\-

Exclusion Criteria

•\-

Key Dates

Last Updated

January 8, 2026

Conditions

Refractory Melanoma

Interventions

Vidutolimod

DRUG

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

TERMINATEDPHASE2

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

NCT04093323

HLA-A2 Positive Cells PresentRefractory Melanoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 8, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

COMPLETEDPHASE2

Study of CP-675,206 in Refractory Melanoma

NCT00254579

Refractory Melanoma

View study